Short Interest in Exicure, Inc. (NASDAQ:XCUR) Increases By 58.5%

Exicure, Inc. (NASDAQ:XCUR) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 44,700 shares, an increase of 58.5% from the February 28th total of 28,200 shares. Approximately 1.8% of the shares of the company are short sold. Based on an average daily trading volume, of 76,100 shares, the short-interest ratio is currently 0.6 days.

Exicure Trading Down 0.1 %

XCUR opened at $13.99 on Monday. The business has a 50 day moving average of $11.08 and a 200-day moving average of $10.06. The stock has a market capitalization of $36.46 million, a price-to-earnings ratio of -6.76 and a beta of 3.84. Exicure has a 1-year low of $1.44 and a 1-year high of $36.00.

Exicure (NASDAQ:XCUR) last released its earnings results on Tuesday, March 18th. The company reported ($3.39) EPS for the quarter.

Institutional Investors Weigh In On Exicure

A hedge fund recently bought a new stake in Exicure stock. Geode Capital Management LLC purchased a new stake in Exicure, Inc. (NASDAQ:XCUR) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 12,645 shares of the company’s stock, valued at approximately $173,000. Geode Capital Management LLC owned approximately 0.48% of Exicure as of its most recent SEC filing. Institutional investors own 42.82% of the company’s stock.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.